Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duloxetine - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Duloxetine - Eli Lilly and Company

Alternative Names: Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Shionogi
  • Class Antidepressants; Antineoplastics; Anxiolytics; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Depressive disorders; Diabetic neuropathies; Fibromyalgia; Generalised anxiety disorder; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Stress incontinence
  • Phase II/III Chronic fatigue syndrome

Most Recent Events

  • 18 Feb 2022 Eli Lilly's data package protection for duloxetine expires in Japan, before February 2022
  • 03 May 2021 Efficacy and adverse events data from a phase III trial in Major depressive disorders presented at the 174th Annual Meeting of the American Psychiatric Association (APA-2021)
  • 05 Aug 2020 Eli Lilly in collaboration with Shionogi terminates a phase III trial in Major depressive disorder (In children, In adolescents) in Japan (PO), due to business decision (NCT03395353)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top